If UVC access is unavailable, neonatal resuscitation guidelines recommend endotracheal (ET) administration. We compared the efficacy of intraosseous (IO) adrenaline to UVC and ET for achieving return of spontaneous circulation (ROSC) in asphyxic near-term lambs.
VERY LOW DOSES OF PHENYLEPHRINE AND CYCLOPENTOLATE EYE DROPS SUFFICIENTLY DILATE THE PUPIL FOR ROP EYE EXAMINATIONS
Background: Premature infants require administration of mydriatic eye drops to dilate the pupil prior to retinopathy of prematurity eye examinations (ROPEE), therefore allowing the Ophthalmologist to perform the ROPEE and view the retina. In New Zealand and Australia, phenylephrine and cyclopentolate are commonly used to dilate the pupil, however there is little evidence guiding the safe and effective use of these eye drops, nor what the lowest effective dose is.
Method: Sixteen premature infants were randomised to receive microdrop administration of phenylephrine 1% or 0.5% and cyclopentolate 0.2% or 0.1%. Efficacy data on pupil dilation, successful ROPEE, and ophthalmologist ease of ROPEE was collected. Safety data on blood pressure, heart rate, oxygen saturations, temperature, feed intolerance, necrotising enterocolitis, and serious adverse drug associated events data was also recorded.
Results: All participants had sufficient pupil dilation for a successful ROPEE. There were no cases of NEC or serious adverse drug events. Preliminary analysis of blood pressure, heart rate, oxygen saturations and temperature indicate no clinically significant adverse events.
Conclusions: Very low microdrop doses of phenylephrine and cyclopentolate eye drops provide sufficient pupil dilation for the ophthalmologist to successfully screen for ROP, while minimising medication adverse effects to the premature infant. To date, this is the first randomised trial evaluating the efficacy and safety of very low microdrop doses of phenylephrine and cyclopentolate. A sufficiently powered randomised controlled trial is required to substantiate these results. Department of Biochemistry, University of Otago, Dunedin, New Zealand Email: mohanraj.krishnan@auckland.ac.nz
Background: The A (minor) allele of CREBRF-rs373863828 is associated with increased BMI but with reduced risk of type 2 diabetes (T2D) in Polynesian people. Given the shared aetiology of T2D and gestational diabetes mellitus (GDM), genetic variants predisposing to T2D may also contribute to GDM risk. We tested for association of rs373863828 with GDM in 112 M aori and Pacific (Polynesian) women with obesity recruited to the Healthy Mums and Babies (HUMBA) Trial.
Methods: Ethnicity was self-reported based on grandparental ethnicity. GDM was defined by 75g oral glucose tolerance test (OGTT) at 24-28 weeks' gestation using the International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria. Unadjusted regression analysis was conducted in the M aori and Pacific groups separately and association effects were combined using meta-analysis.
Results: Participants had a mean (SD) baseline BMI of 39.2 (6.1) kg/m 2 . GDM was present in 35 (31%) women (16% in M aori women, 39% in Pacific women). CREBRF-rs373863828 was carried by 39 (29%) women (34% in M aori women, 27% in Pacific women). Each allele was associated with a 5-fold reduction in the odds of GDM (OR = 0.20 [0.06, 0.68] , P = 0.01) and 0.49 mmol/L lower 2-h OGTT glucose concentration (β = −0.49 [−0.86,−0.12], P = 0.01). CREBRF-rs373863828 was not associated with BMI, although in Pacific women it tended towards association with higher gestational weight gain (β = 2.91 [0.02, 5.80], P = 0.05).
Conclusions: CREBRF-rs373863828 is associated with a substantially reduced likelihood of GDM in M aori and Pacific women. Future research will determine whether CREBRF genotyping can improve GDM risk stratification in M aori and Pacific women.
